Pardoprunox

Pardoprunox (INN) (code name SLV-308) is an antiparkinsonian drug currently that was under development by Solvay for the treatment of Parkinson's disease that reached phase III clinical trials before being discontinued.[1] It was also being investigated for the treatment of depression and anxiety but these indications appear to have been abandoned as well.

Pardoprunox acts as a D₂ (pK_i = 8.1) and D₃ receptor (pK_i = 8.6) partial agonist (IA = 50% and 67%, respectively) and 5-HT_1A receptor (pK_i = 8.5) full agonist (IA = 100%). It also binds to D₄ (pK_i = 7.8), α₁-adrenergic (pK_i = 7.8), α₂-adrenergic (pK_i = 7.4), and 5-HT₇ receptors (pK_i = 7.2) with lower affinity. Relative to other dopaminergic antiparkinsonian agents, pardoprunox is thought to have significantly less of a propensity for inducing certain side effects like dyskinesia and psychosis.